The Director, National Accounts role is an opportunity for an experienced payer account executive to help launch apitegromab, Scholar Rock’s investigational drug for the treatment of Spinal Muscular Atrophy (SMA). This team will have a direct impact on our ability to deliver value to patients and the trajectory of the company’s first launch. This role will be accountable for establishing Scholar Rock’s presence with key payers, achieving rapid, appropriate coverage for apitegromab in assigned accounts and regions, and supporting ongoing patient access efforts through launch.
Position Responsibilities:
- Lead account planning, management, and engagement activities at assigned payers to achieve rapid and clinically appropriate access for patients. This includes establishing and further developing relationships with decision makers at key customers
- Support development of apitegromab’s value proposition and other supporting materials, including any account-specific needs
- Maintain a strong understanding of apitegromab Commercial objectives and how to help achieve these goals through assigned accounts
- Work across teams to ensure patient access objectives are met, including pull-through
- Ensure all programs are aligned to Scholar Rock values and remain compliant with regulations
- Lead presence with target accounts at access-related meetings, events and congresses (e.g., AMCP, PCMA, Asembia, Medicaid meetings, etc)
- Collaborate with Insights and Analytics and Commercial Operations to derive account-level insights and actions; communicate access and coverage performance regularly to internal stakeholders
- Proactively identify and execute against opportunities to improve patient access to care, within and outside of Value & Access
- Be a content expert on relevant industry trends, market dynamics, policy and legislation and define implications and actions for Scholar Rock
- Be a collaborative, strategic market access presence throughout the Scholar Rock organization
Candidate Requirements:
- Bachelors degree
- At least 6 years’ experience in US Market Access with a deep understanding of evolving access, coverage, and reimbursement landscape
- Experience and relationships with national and key regional Commercial, Medicaid, and other Government payers. Experience with VA/DoD/Tricare and Humana are strongly encouraged
- Proven track record of achieving rapid, broad, and clinically appropriate coverage for medical benefit and/or rare disease products at launch
- Comprehensive understanding of payer decision making bodies and cycles, processes/procedures, and data and reporting
- Experience negotiating agreements with large healthcare systems preferred
- Pre-launch experience at a small, start-up biotechnology company preferred
Skills Required
- Bachelors degree
- At least 6 years' experience in US Market Access
- Experience with national and key regional payers
- Track record of achieving coverage for medical benefit products
- Understanding of payer decision-making processes
- Experience negotiating agreements with large healthcare systems
- Pre-launch experience at a biotechnology company
What We Do
Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, the company has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role. Scholar Rock is the only company to show clinical proof of concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about the company’s approach at ScholarRock.com and follow @ScholarRock and on LinkedIn. For additional information on our guidelines, please visit https://scholarrock.com/community-guidelines/ For more information on how Scholar Rock collects, uses, and shares personal information, please visit: https://scholarrock.com/privacy-policy
